Varban M L, Rinninger F, Wang N, Fairchild-Huntress V, Dunmore J H, Fang Q, Gosselin M L, Dixon K L, Deeds J D, Acton S L, Tall A R, Huszar D
Millennium Pharmaceuticals, Inc., 640 Memorial Drive, Cambridge, MA 02139, USA.
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4619-24. doi: 10.1073/pnas.95.8.4619.
Scavenger receptor BI (SR-BI) is a cell surface receptor that binds high density lipoproteins (HDL) and mediates selective uptake of HDL cholesteryl esters (CE) in transfected cells. To address the physiological role of SR-BI in HDL cholesterol homeostasis, mice were generated bearing an SR-BI promoter mutation that resulted in decreased expression of the receptor in homozygous mutant (designated SR-BI att) mice. Hepatic expression of the receptor was reduced by 53% with a corresponding increase in total plasma cholesterol levels of 50-70% in SR-BI att mice, attributable almost exclusively to elevated plasma HDL. In addition to increased HDL-CE, HDL phospholipids and apo A-1 levels were elevated, and there was an increase in HDL particle size in mutant mice. Metabolic studies using HDL bearing nondegradable radiolabels in both the protein and lipid components demonstrated that reducing hepatic SR-BI expression by half was associated with a decrease of 47% in selective uptake of CE by the liver, and a corresponding reduction of 53% in selective removal of HDL-CE from plasma. Taken together, these findings strongly support a pivotal role for hepatic SR-BI expression in regulating plasma HDL levels and indicate that SR-BI is the major molecule mediating selective CE uptake by the liver. The inverse correlation between plasma HDL levels and atherosclerosis further suggests that SR-BI may influence the development of coronary artery disease.
清道夫受体BI(SR-BI)是一种细胞表面受体,可结合高密度脂蛋白(HDL)并介导转染细胞中HDL胆固醇酯(CE)的选择性摄取。为了研究SR-BI在HDL胆固醇稳态中的生理作用,构建了带有SR-BI启动子突变的小鼠,该突变导致纯合突变体(称为SR-BI att)小鼠中受体表达降低。SR-BI att小鼠肝脏中该受体的表达降低了53%,血浆总胆固醇水平相应升高了50%-70%,几乎完全归因于血浆HDL升高。除了HDL-CE增加外,HDL磷脂和载脂蛋白A-1水平也升高,并且突变小鼠中HDL颗粒大小增加。使用蛋白质和脂质成分均带有不可降解放射性标记的HDL进行的代谢研究表明,将肝脏SR-BI表达降低一半与肝脏对CE的选择性摄取降低47%以及从血浆中选择性清除HDL-CE相应降低53%相关。综上所述,这些发现有力地支持了肝脏SR-BI表达在调节血浆HDL水平中的关键作用,并表明SR-BI是介导肝脏选择性摄取CE的主要分子。血浆HDL水平与动脉粥样硬化之间的负相关进一步表明,SR-BI可能影响冠状动脉疾病的发展。